Industries: Biotech & Pharma
Technologies: Biotech & Synthetic Biology Other fields: -
Funding stage: Founded: 2011 Employees:
Business model: Other types of licence Target: Business
Iproteos seeks to improve human health by creating therapeutics for diseases that are currently difficult to target. Our IPROTech platform quickly and efficiently delivers cell-permeable and bio-available drug candidates to modulate "undruggable" targets. The effectiveness of IPROTech has been proved by Iproteos' pipeline and in multiple ongoing strategic partnerships.
Minority stake unknown %
Investors: CAIXA CAPITAL RISC, KINLED HOLDING LTD, ASCIL PROYECTOS SL, EMPRESA NACIONAL DE INNOVACION SA
Minority stake unknown %
Investors: CAPITAL CELL
Minority stake
Investors: UNDISCLOSED PRIVATE INVESTORS
Source: Press releases newsletters & platforms company websites annual reports & accounts regulatory body sites & stock exchanges
We are continually updating our list of new startups so please let us know if you have recently started one.
It is a Catalan Government project offering updated information on the Catalan startup ecosystem; gathering and consolidating data from internal databases as well as other local and international sources.